The global cardiovascular clinical trials market size was estimated to be USD 5.59 billion in 2023 and is expected to reach at USD 10.84 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034. Rising prevalence of cardiovascular diseases such as stroke, heart failure, & coronary artery diseases, increasing investment by government & market players, surge in demand for cost reduction within Phase III trials, growing advancements in medical research including personalized medicine & genomics, rising technological progress in medical research, with the adoption of telemedicine & wearable devices for remote monitoring of clinical trial participants, and increasing need for enhanced cardiovascular treatments involving new therapies and medications are some of the key factors boosting the market growth.
Increasing need for enhanced cardiovascular treatments, involving new therapies and medications, is driving the requirement for clinical trials on drugs designed to address cardiovascular diseases. As a result, the substantial number of clinical trials focused on the latest treatments and therapies for managing the significant cardiovascular disease burden is contributing to market expansion. For instance, in August 2023, Novo Nordisk has revealed the headline findings from the SELECT cardiovascular outcomes trial. In this double-blinded study, subcutaneous once-weekly Semaglutide 2.4 mg was compared to a placebo as an addition to the standard of care for preventing major adverse cardiovascular events (MACEs) over a potential duration of up to five years. The trial involved 17,604 adults aged 45 years or older, who had overweight or obesity and had a history of established cardiovascular disease (CVD) but no prior diabetes diagnosis.
By phase, phase IV was the highest revenue-grossing segment in the global cardiovascular clinical trials market in 2023 owing to growing need for post-marketing studies to regularly evaluate the effectiveness & safety of cardiovascular treatments, driven by regulatory bodies such as the U.S. FDA and European Union regulatory agencies and rising availability of patient data & advancements in genomics are driving the need to investigate the advantages of incorporating real-world data into clinical trials. Additionally, phase I is predicted to grow at fastest CAGR during the forecast period owing to the growing number of products in the pipeline entering Phase I clinical trials and surge in investment for research & development endeavours aimed at enhancing healthcare & delivering novel and enhanced cardiovascular treatments through the execution of clinical trials. For instance, in June 2023, As stated in an article published by Pharma Manufacturing, the research and development (R&D) landscape in the pharmaceutical industry is marked by a substantial drug pipeline, which includes a total of 21,292 drugs in different stages ranging from preclinical development to post-market surveillance.
By style design, interventional was the highest revenue-grossing segment in the global cardiovascular clinical trials market in 2023 owing to the increase in the number of interventional studies conducted over time, rising demand for enhanced precision & applicability compared to observational studies, and a significant increase in the release of clinical trial findings. For instance, in August 2023, Amgen presented data from the concluding analysis of the Phase 2 OCEAN(a)-DOSE study featuring olpasiran, a small interfering RNA (siRNA), during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting in Amsterdam. In the off-treatment extension phase, olpasiran exhibited a sustained impact on reducing Lp(a) levels, persisting for nearly a year after the last administered dose. Additionally, observational is predicted to grow at fastest CAGR during the forecast period owing to its cost-effectiveness. Observational trials enable clinical researchers to collect real-world data regarding the impact of interventions or treatments in actual clinical settings, extending beyond the controlled conditions of traditional clinical trials. These trials offer a more comprehensive view of treatment outcomes across various demographic groups, often involving larger and more diverse patient populations.
By indication, coronary artery disease was the highest revenue-grossing segment in the global cardiovascular clinical trials market in 2023 owing to the rising prevalence of coronary artery disease, increasing quantity of clinical trials focusing on coronary artery disease currently undergoing evaluation. For instance, in August 2023, Bristol Myers Squibb has announced its participation in the European Society of Cardiology (ESC) Congress, taking place both in-person and virtually from August 25 to 28, 2023. The company will present research that reinforces the strength of its comprehensive cardiovascular portfolio. The presentations will include data from clinical studies, such as cumulative analyses of CAMZYOS (mavacamten) up to 120 weeks, its impact on standard of care (SOC) medication from the EXPLORER cohort of the MAVA-long-term extension (LTE) study, and a late-breaking presentation of VALOR-HCM-LTE 56-week data. Additionally, new data from health economics outcomes research will be shared. The Bristol Myers Squibb-Pfizer Alliance will also present findings from an observational retrospective real-world study on the clinical impact of switching or continuing treatment with Eliquis® (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF). Additionally, stroke is predicted to grow at fastest CAGR during the forecast period owing to the growing incidence of uncertain cardiac strokes, and surge in research & development activities.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of well-established Contract Research Organizations (CROs) that specialize in cardiovascular clinical trials, surge in improvement of healthcare infrastructure, increasing uptake of various innovative & pioneering technologies in clinical research, and rising initiatives by market players. For instance, in October 2022, Q² Solutions, a wholly owned subsidiary of IQVIA and a prominent global provider of clinical trial laboratory services, has introduced the first self-collection safety lab panel for clinical trial participants in the United States. This initiative marks a significant development in the field of clinical trial laboratory services. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the regulatory reforms that offer support and cost-effective alternatives for conducting clinical research, surge in research & development activities, and growing number of clinical trial procedures. For instance, in August 2023, The VALOR-HCM trial demonstrated that Mavacamten effectively alleviated symptoms and notably reduced the need for septal reduction therapy (SRT) among symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) who were contemplating SRT and were already on the highest tolerated medical treatment. The primary objective of the trial was to evaluate the safety and efficacy of incorporating mavacamten into the existing maximally tolerated medical therapy for patients with obstructive HCM.
Increasing need for enhanced cardiovascular treatments, involving new therapies and medications, is driving the requirement for clinical trials on drugs designed to address cardiovascular diseases. As a result, the substantial number of clinical trials focused on the latest treatments and therapies for managing the significant cardiovascular disease burden is contributing to market expansion. For instance, in August 2023, Novo Nordisk has revealed the headline findings from the SELECT cardiovascular outcomes trial. In this double-blinded study, subcutaneous once-weekly Semaglutide 2.4 mg was compared to a placebo as an addition to the standard of care for preventing major adverse cardiovascular events (MACEs) over a potential duration of up to five years. The trial involved 17,604 adults aged 45 years or older, who had overweight or obesity and had a history of established cardiovascular disease (CVD) but no prior diabetes diagnosis.
By phase, phase IV was the highest revenue-grossing segment in the global cardiovascular clinical trials market in 2023 owing to growing need for post-marketing studies to regularly evaluate the effectiveness & safety of cardiovascular treatments, driven by regulatory bodies such as the U.S. FDA and European Union regulatory agencies and rising availability of patient data & advancements in genomics are driving the need to investigate the advantages of incorporating real-world data into clinical trials. Additionally, phase I is predicted to grow at fastest CAGR during the forecast period owing to the growing number of products in the pipeline entering Phase I clinical trials and surge in investment for research & development endeavours aimed at enhancing healthcare & delivering novel and enhanced cardiovascular treatments through the execution of clinical trials. For instance, in June 2023, As stated in an article published by Pharma Manufacturing, the research and development (R&D) landscape in the pharmaceutical industry is marked by a substantial drug pipeline, which includes a total of 21,292 drugs in different stages ranging from preclinical development to post-market surveillance.
By style design, interventional was the highest revenue-grossing segment in the global cardiovascular clinical trials market in 2023 owing to the increase in the number of interventional studies conducted over time, rising demand for enhanced precision & applicability compared to observational studies, and a significant increase in the release of clinical trial findings. For instance, in August 2023, Amgen presented data from the concluding analysis of the Phase 2 OCEAN(a)-DOSE study featuring olpasiran, a small interfering RNA (siRNA), during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting in Amsterdam. In the off-treatment extension phase, olpasiran exhibited a sustained impact on reducing Lp(a) levels, persisting for nearly a year after the last administered dose. Additionally, observational is predicted to grow at fastest CAGR during the forecast period owing to its cost-effectiveness. Observational trials enable clinical researchers to collect real-world data regarding the impact of interventions or treatments in actual clinical settings, extending beyond the controlled conditions of traditional clinical trials. These trials offer a more comprehensive view of treatment outcomes across various demographic groups, often involving larger and more diverse patient populations.
By indication, coronary artery disease was the highest revenue-grossing segment in the global cardiovascular clinical trials market in 2023 owing to the rising prevalence of coronary artery disease, increasing quantity of clinical trials focusing on coronary artery disease currently undergoing evaluation. For instance, in August 2023, Bristol Myers Squibb has announced its participation in the European Society of Cardiology (ESC) Congress, taking place both in-person and virtually from August 25 to 28, 2023. The company will present research that reinforces the strength of its comprehensive cardiovascular portfolio. The presentations will include data from clinical studies, such as cumulative analyses of CAMZYOS (mavacamten) up to 120 weeks, its impact on standard of care (SOC) medication from the EXPLORER cohort of the MAVA-long-term extension (LTE) study, and a late-breaking presentation of VALOR-HCM-LTE 56-week data. Additionally, new data from health economics outcomes research will be shared. The Bristol Myers Squibb-Pfizer Alliance will also present findings from an observational retrospective real-world study on the clinical impact of switching or continuing treatment with Eliquis® (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF). Additionally, stroke is predicted to grow at fastest CAGR during the forecast period owing to the growing incidence of uncertain cardiac strokes, and surge in research & development activities.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of well-established Contract Research Organizations (CROs) that specialize in cardiovascular clinical trials, surge in improvement of healthcare infrastructure, increasing uptake of various innovative & pioneering technologies in clinical research, and rising initiatives by market players. For instance, in October 2022, Q² Solutions, a wholly owned subsidiary of IQVIA and a prominent global provider of clinical trial laboratory services, has introduced the first self-collection safety lab panel for clinical trial participants in the United States. This initiative marks a significant development in the field of clinical trial laboratory services. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the regulatory reforms that offer support and cost-effective alternatives for conducting clinical research, surge in research & development activities, and growing number of clinical trial procedures. For instance, in August 2023, The VALOR-HCM trial demonstrated that Mavacamten effectively alleviated symptoms and notably reduced the need for septal reduction therapy (SRT) among symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) who were contemplating SRT and were already on the highest tolerated medical treatment. The primary objective of the trial was to evaluate the safety and efficacy of incorporating mavacamten into the existing maximally tolerated medical therapy for patients with obstructive HCM.
Segmentation: Cardiovascular Clinical Trials Market Report 2023 - 2034
Cardiovascular Clinical Trials Market Analysis & Forecast by Phase 2023 - 2034 (Revenue USD Bn)
- Phase IV
- Phase III
- Phase II
- Phase I
Cardiovascular Clinical Trials Market Analysis & Forecast by Style Design 2023 - 2034 (Revenue USD Bn)
- Observational
- Expanded Access
- Interventional
Cardiovascular Clinical Trials Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Stroke
- Heart Failure
- Ischemic Heart Disease
- Coronary Artery Disease
- Cardiac Arrhythmias
- Acute Coronary Syndrome
- Pulmonary Arterial Hypertension
- Others
Cardiovascular Clinical Trials Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cardiovascular Clinical Trials Market: Phase Estimates & Trend Analysis
8. Cardiovascular Clinical Trials Market: Style Design Estimates & Trend Analysis
9. Cardiovascular Clinical Trials Market: Indication Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cardiovascular Clinical Trials Market
12. Europe Global Cardiovascular Clinical Trials Market
13. Asia Pacific Global Cardiovascular Clinical Trials Market
14. Latin America Global Cardiovascular Clinical Trials Market
15. MEA Global Cardiovascular Clinical Trials Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- IQVIA Inc
- Pfizer Inc
- Worldwide Clinical Trials
- PPD Inc
- Novo Nordisk
- Syneos Health
- Medpace Inc.
- Caidya
- SGS SA
- ICON plc
- Vial
- Veeda Clinical Research
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.59 Billion |
| Forecasted Market Value ( USD | $ 10.84 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
